Gradient Investments’s CRISPR Therapeutics CRSP Stock Holding History

Gradient Investments’s Portfolio CRSP Stock Details CRSP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	–	Sell	-25	Closed	-$1.35K	–	508
2024 Q2	$1.35K	Hold	25	–	–	﹤0.01%	1038
2024 Q1	$1.7K	Hold	25	–	–	﹤0.01%	847
2023 Q4	$1.56K	Hold	25	–	–	﹤0.01%	1302
2023 Q3	$1.14K	Hold	25	–	–	﹤0.01%	1329
2023 Q2	$1.4K	Hold	25	–	–	﹤0.01%	1263
2023 Q1	$1.13K	Hold	25	–	–	﹤0.01%	1189
2022 Q4	$1.02K	Hold	25	–	–	﹤0.01%	1194
2022 Q3	$2K	Hold	25	–	–	﹤0.01%	1126
2022 Q2	$2K	Sell	25 -38	-60%	-$2.23K	﹤0.01%	1034
2022 Q1	$4K	Buy	63 +25	+66%	+$1.57K	﹤0.01%	917
2021 Q4	$3K	Hold	38	–	–	﹤0.01%	1005
2021 Q3	$4K	Hold	38	–	–	﹤0.01%	908
2021 Q2	$6K	Hold	38	–	–	﹤0.01%	843
2021 Q1	$5K	Hold	38	–	–	﹤0.01%	876
2020 Q4	$3K	Hold	38	–	–	﹤0.01%	878
2020 Q3	$3K	Hold	38	–	–	﹤0.01%	884
2020 Q2	$3K	Sell	38 -9	-19%	-$526	﹤0.01%	821
2020 Q1	$2K	Buy	+47	New	+$2.43K	﹤0.01%	900

Other funds holding CRSP

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

Gradient Investments's CRSP Position: Q3 2024 in Review

Gradient Investments sold out of CRISPR Therapeutics (CRSP) in Q3 2024, closing a stake of 25 shares — an estimated $1.35K sold.

Gradient Investments first reported a position in CRSP in Q1 2020 and held it in 18 quarters. The position peaked at $6K in Q2 2021. 416 funds tracked by Wall St. Rank hold CRSP as of Q3 2024.

Gradient Investments reported no remaining CRISPR Therapeutics position as of Q3 2024 after selling out during the quarter.
Gradient Investments sold 25 CRISPR Therapeutics shares in Q3 2024, an estimated $1.35K.
Gradient Investments first reported a position in CRISPR Therapeutics in Q1 2020 and held it in 18 quarters.
Gradient Investments's CRISPR Therapeutics position peaked at $6K in Q2 2021.
416 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q3 2024.

Based on Gradient Investments's 13F filing for Q3 2024, filed 15 Oct 2024.